Evidence map›Paper›PMID 39033629›Full record

ArticleMolecular genetics and metabolism

Reduction of neuroinflammation and seizures in a mouse model of CLN1 batten disease using the small molecule enzyme mimetic, N-Tert-butyl hydroxylamine.

Zach Fyke, Rachel Johansson, Anna I Scott, Devin Wiley, Daniel Chelsky, Joseph D Zak, Nader Al Nakouzi, Kevin P Koster, Akira Yoshii

Abstract read
In one paragraph

Article in Molecular genetics and metabolism. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Altered Protein Palmitoylation as Disease Mechanism in Neurodegenerative Disorders.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zach FykeDepartment of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, IL, United States of America.
Rachel JohanssonSchool of Medicine, University of California Davis, Sacramento, CA, United States of America; Circumvent Pharmaceuticals, Portland, OR, United States of America.
Anna I ScottCircumvent Pharmaceuticals, Portland, OR, United States of America; Department of Laboratories, Seattle Children's Hospital, Seattle, WA, United States of America.
Devin WileyCircumvent Pharmaceuticals, Portland, OR, United States of America.
Daniel ChelskyCircumvent Pharmaceuticals, Portland, OR, United States of America.
Joseph D ZakDepartment of Biological Sciences, University of Illinois at Chicago, Chicago, IL, United States of America; Department of Psychology University of Illinois at Chicago, Chicago, IL, United States of America.
Nader Al NakouziCircumvent Pharmaceuticals, Portland, OR, United States of America. Electronic address: naderalnakouzi@gmail.com.
Kevin P KosterDepartment of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, IL, United States of America; Department of Neurobiology, University of Chicago, Chicago, IL, United States of America. Electronic address: kpkoster@uchicago.edu.
Akira YoshiiDepartment of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, IL, United States of America; Department of Pediatrics, University of Illinois at Chicago, Chicago, IL, United States of America; Department of Neurology, University of Illinois at Chicago, Chicago, IL, United States of America.

Funding

Development of N-tert-(Butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating Infantile Neuronal Ceroid Lipofuscinosis (INCL)R44NS120360 · NINDS · CIRCUMVENT PHARMACEUTICALS, INC. · PI DANIEL CHELSKY, Robert David Steiner · 2021 to 2026
$5.4M
Learning-mediated plasticity in cortical feedback projections to the olfactory bulbR00DC017754 · NIDCD · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ZAK, JOSEPH DONALD · 2022 to 2024
$918k
Development of a protein palmitoylation assay to monitor treatment of CLN1 Batten DiseaseR41HD105560 · NICHD · CIRCUMVENT PHARMACEUTICALS, INC. · PI FOSTER, MATTHEW WOLF, SCOTT, ANNA INGRID · 2021 to 2021
$305k
Learning-mediated plasticity in cortical feedback projections to the olfactory bulbK99DC017754 · NIDCD · HARVARD UNIVERSITY · PI ZAK, JOSEPH DONALD · 2020 to 2021
$257k
NICHD NIH HHS R41 HD105560NIDCD NIH HHS K99 DC017754NIDCD NIH HHS R00 DC017754NINDS NIH HHS R44 NS120360
6 · The paper itself

Abstract

Infantile neuronal ceroid lipofuscinosis (CLN1 Batten Disease) is a devastating pediatric lysosomal storage disease caused by pathogenic variants in the CLN1 gene, which encodes the depalmitoylation enzyme, palmitoyl-protein thioesterase 1 (PPT1). CLN1 patients present with visual deterioration, psychomotor dysfunction, and recurrent seizures until neurodegeneration results in death, typically before fifteen years of age. Histopathological features of CLN1 include aggregation of lysosomal autofluorescent storage material (AFSM), as well as profound gliosis. The current management of CLN1 is relegated to palliative care. Here, we examine the therapeutic potential of a small molecule PPT1 mimetic, N-tert-butyl hydroxylamine (NtBuHA), in a Cln1

Indexed as

Disease Models, AnimalNeuronal Ceroid-LipofuscinosesSeizuresThiolester HydrolasesAnimalsHumansHydroxylaminesLysosomesMiceMice, KnockoutNeuroinflammatory DiseasesNeuronsHydroxylaminespalmitoyl-protein thioesteraseThiolester HydrolasesBatten diseaseInfantile neuronal ceroid lipofuscinosisNeurodegenerationNeuroinflammationPalmitoyl-protein thioesteraseSeizureSmall molecule therapeuticSynapse calcium

Identifiers

PMID39033629
PMCPMC11473239

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.